Cure My Disease

Don't miss your cure!

 Log in / Sign up

New vaginal tablet could ease menopause discomfort

NCT ID NCT06197568

Recruiting now Symptom relief Sponsor: Azure Biotech Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a vaginal tablet called AZU-101 (lasofoxifene) in 90 postmenopausal women aged 45-60 who have vaginal atrophy, causing dryness and pain during sex. The tablet is given daily for 14 days to see if it is safe and can improve vaginal cell health and lower vaginal pH. Half the participants will get the active drug and half a placebo, and neither they nor the doctors will know which they received.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Lasofoxifene tartrate (AZU-101) vaginal tablet
What this could lead to
If successful, this could provide a new, locally-acting treatment option for vaginal atrophy that eases discomfort and improves quality of life in postmenopausal women.
What could go wrong
This is an early Phase 2 proof-of-concept study with only 90 participants. The treatment may not prove effective or safe enough to advance, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POSTMENOPAUSAL SYMPTOMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

postmenopausal atrophic vaginitis psychologic dyspareunia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POSTMENOPAUSAL SYMPTOMS VULVO VAGINAL ATROPHY (VVA)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Nucleus Network

    RECRUITING

    Saint Paul, Minnesota, 55114, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.